Login to Your Account

Morphotek's Ovarian Cancer Drug Fails in Phase III Study

By Catherine Shaffer
Staff Writer

Monday, January 14, 2013
Morphotek Inc.'s promising ovarian cancer drug farletuzumab yielded disappointing results in a Phase III trial in ovarian cancer. The study, which combined farletuzumab with carboplatin and taxane in platinum-sensitive epithelial ovarian cancer, did not meet its primary endpoint of progression-free survival (PFS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription